US Drug Recall Register

FDA Drug Recalls

2,661 recalls, newest first

Class II · Moderate risk Ongoing

Wegovy

Reason Presence of Particulate Matter: Hair was found in a prefilled syringe

Novo Nordisk Inc. NDC 0169-4501-14 D-0245-2026
Class II · Moderate risk Ongoing

Wegovy

Reason Presence of Particulate Matter: Hair was found in a prefilled syringe

Novo Nordisk Inc. NDC 0169-4505-14 D-0244-2026
Class II · Moderate risk Ongoing

Tri-Moxi+¿

Reason Presence of particulate matter - Glass like particles.

Imprimis NJOF, LLC NDC 71384-746-06 D-0251-2026
Class II · Moderate risk Ongoing

Dexamethasone Moxifloxacin Ketorolac

Reason Presence of particulate matter - Glass like particles.

Imprimis NJOF, LLC NDC 71384-513-01 D-0250-2026
Class II · Moderate risk Ongoing

Dexamethasone Moxifloxacin

Reason Presence of particulate matter - Glass like particles.

Imprimis NJOF, LLC NDC 71384-512-0 D-0249-2026
Class II · Moderate risk Ongoing

BD ChloraPrep" Triple Swabsticks

Reason Lack of Assurance of Sterlity

CareFusion 213, LLC NDC 54365-401-29 D-0243-2026
Class II · Moderate risk Ongoing

Oxycodone and Acetaminophen CII Tablets USP

Reason Failed Tablet/Capsule Specification: There is a potential for the imprint to be missing on tablets.

SpecGx, LLC NDC 0406-0522-01 D-0255-2026
Class II · Moderate risk Ongoing

Oxycodone and Acetaminophen CII Tablets USP

Reason Failed Tablet/Capsule Specification: There is a potential for the imprint to be missing on tablets.

SpecGx, LLC NDC 0406-0523-01 D-0254-2026
Class III · Low risk Ongoing

Fesoterodine Fumarate

Reason Failed Impurities/Degradation Specifications: Due to levels of 'Diester Impurity' exceeding the specification limit.

Alembic Pharmaceuticals Limited NDC 62332-176-30 D-0248-2026
Class I · High risk Ongoing

MR. 7 SUPER 700000 capsules

Reason Marketed Without an Approved NDA/ANDA: FDA analysis revealed the presence of undeclared sildenafil and tadalafil

StuffbyNainax D-0397-2026
Class III · Low risk Ongoing

Glycopyrrolate Oral Solution

Reason Failed Impurities/Degradation Specifications

Novadoz Pharmaceuticals LLC NDC 72205-070-72 D-0300-2026
Class I · High risk Ongoing

ClearLife Allergy Nasal Spray

Reason Microbial Contamination of Non-Sterile Products: The products have been found to contain yeast/mold and microbial contamination identified as Achromobacter.

Medinatura New Mexico, inc. NDC 62795-4006-9 D-0289-2026
Class I · High risk Ongoing

ReBoost Nasal Spray

Reason Microbial Contamination of Non-Sterile Products: The products have been found to contain yeast/mold and microbial contamination identified as Achromobacter.

Medinatura New Mexico, inc. NDC 62795-4005-9 D-0288-2026
Class II · Moderate risk Ongoing

Noxafil Powdermix

Reason Presence of particulate matter: potential presence of metal particulates in the product.

Merck Sharp & Dohme LLC NDC 0085-2224-02 D-0242-2026
Class II · Moderate risk Ongoing

Merck Emend

Reason Presence of particulate matter: potential presence of metal particulates in the product.

Merck Sharp & Dohme LLC NDC 0006-3066-03 D-0241-2026
Class II · Moderate risk Ongoing

Ciclopirox Shampoo

Reason Failed Impurity/Degradation specifications: OOS results obtained at the 18-month timepoint

Sun Pharma /Taro NDC 51672-1351-08 D-0240-2026
Class II · Moderate risk Ongoing

ORL Kids Natural Toothpaste

Reason cGMP Deviations

Signature Formulations, LLC D-0253-2026
Class II · Moderate risk Ongoing

ORL Kids Mouthwash

Reason cGMP Deviations

Signature Formulations, LLC D-0252-2026
Class III · Low risk Ongoing

Clindamycin Phosphate USP

Reason Failed Impurities/Degradation: Out of Specification results for Total Impurities and for Assay.

Sun Pharmaceutical Industries INC NDC 51672-4081-4 D-0257-2026
Class III · Low risk Ongoing

Cisatracurium Besylate Injection USP

Reason Subpotent product:out of specification assay results observed during long term stability testing.

Somerset Therapeutics LLC NDC 70069-161-01 D-0238-2026
Class III · Low risk Ongoing

Cisatracurium Besylate Injection USP

Reason Subpotent product:out of specification assay results observed during long term stability testing.

Somerset Therapeutics LLC NDC 70069-151-01 D-0237-2026
Class III · Low risk Ongoing

Cisatracurium Besylate Injection USP

Reason Subpotent product:out of specification assay results observed during long term stability testing.

Somerset Therapeutics LLC NDC 70069-141-01 D-0236-2026
Class II · Moderate risk Ongoing

Baclofen Tablets USP

Reason Presence of Foreign Tablets/Capsules

Golden State Medical Supply Inc. NDC 51407-973-10 D-0235-2026
Class III · Low risk Ongoing

Morphine Sulfate Oral Solution 100 mg / 5 mL

Reason Correct Labeled Product Mispack-Size stated on carton label did not match the size of the bottle in the carton.

Winder Laboratories, LLC D-0223-2026
Class II · Moderate risk Ongoing

Duloxetine Delayed-Release Capsules

Reason CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit

Breckenridge Pharmaceutical, Inc. NDC 51991-748-10 D-0216-2026